HE4 As Prognostic Marker In Endometrial Cancer
Rewriter
Member Posts: 493 Member
The 17th International European Society of Gynaecological Oncology (ESGO) meeting runs from September 11 through the 14th in Milan, Italy. One interesting topic to be presented is the use of HE4 as a prognostic market in endometrial cancer. The abstract for this presentation is pasted below. I will follow up with any information that is shared when the meeting ends. I assume that HE4 testing will render the CA-125 obsolete for detecting recurrence.
"The HE4 (human epididymis protein4) has been shown to have the potential to differentiate between benign endometrial disease and endometrial cancer. The data presented will provide evidence that the HE4 serum levels are an independent prognostic markers for endometrial cancer patients."
Jill
"The HE4 (human epididymis protein4) has been shown to have the potential to differentiate between benign endometrial disease and endometrial cancer. The data presented will provide evidence that the HE4 serum levels are an independent prognostic markers for endometrial cancer patients."
Jill
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.9K Cancer specific
- 2.8K Anal Cancer
- 446 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 398 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 671 Leukemia
- 794 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 237 Multiple Myeloma
- 7.1K Ovarian Cancer
- 63 Pancreatic Cancer
- 487 Peritoneal Cancer
- 5.5K Prostate Cancer
- 1.2K Rare and Other Cancers
- 540 Sarcoma
- 734 Skin Cancer
- 653 Stomach Cancer
- 191 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.9K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards